Research Article| Volume 19, ISSUE 1, P62-72, January 1997

Improved mealtime treatment of diabetes mellitus using an insulin analogue

      This paper is only available as a PDF. To read, Please Download here.


      The absorption of regular human insulin from subcutaneous injection sites is delayed due to the self-association of insulin to multimeric forms. The insulin analogue insulin lispro has a weak self-association and a fast absorption rate. We examined the safety and efficacy of insulin lispro in the premeal treatment of patients with diabetes mellitus. A 12-month study was performed in 336 patients with insulin-dependent diabetes mellitus (IDDM) and 295 patients with non-insulin-dependent diabetes mellitus (NIDDM). The patients were randomized to inject either regular human insulin 30 to 45 minutes before eating, or insulin lispro immediately before each meal, in addition to basal insulin. The postprandial rise in serum glucose was lower in patients receiving insulin lispro than in those receiving regular human insulin therapy. At end point, the increment was significantly lower at 1 hour (35%) and at 2 hours (64%) after the meal in IDDM patients; in NIDDM patients, the increment was nonsignificantly lower at 1 hour (19%) and significantly lower at 2 hours (48%). IDDM patients receiving insulin lispro achieved significantly lower glycated hemoglobin (HbA1c) levels in patients receiving regular human insulin (8.1% vs 8.3%. In NIDDM patients, HbA1c levels decreased equally in both treatment groups. Due to its fast absorption rate, insulin lispro improves postprandial control in diabetes. Insulin lispro can be considered one step toward optimal insulin therapy and improved patient convenience.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Binder C
        Absorption of injected insulin: A clinical-pharmacological study.
        Acta Pharmacol Toxicol. 1969; 27 (Suppl 2): 1-84
        • Galloway JA
        • Spradlin CT
        • Nelson RL
        • et al.
        Factors influencing the absorption, serum insulin concentration, and blood glucose response after injections of regular insulin and various mixtures.
        Diabetes Care. 1981; 4: 366-376
        • Berger M
        • Cüppers HJ
        • Hegner H
        • et al.
        Absorption kinetics and biologic effects of subcutaneously injected insulin preparations.
        Diabetes Care. 1982; 5: 77-91
        • Malherbe C
        • de Gasparo M
        • de Hertogh R
        • Hoet JJ
        Circadian variations of blood sugar and plasma insulin levels in man.
        Diabetologia. 1969; 5: 397-404
        • Eaton RP
        • Allen RC
        • Schade DS
        • Standefer JC
        “Normal” insulin secretion: The goal of artificial insulin delivery systems.
        Diabetes Care. 1980; 3: 270-273
        • American Diabetes Association
        Clinical Practice Recommendations 1995. Position statement: Insulin administration.
        Diabetes Care. 1995; 18 (Suppl 1): 29-32
        • Lean MEJ
        • Ng LL
        • Tennison BR
        Interval between insulin injection and eating in relation to blood glucose control in adult diabetics.
        BMJ. 1985; 290: 105-108
        • Jørgensen LN
        • Nielsen FS
        Timing of premeal insulins in diabetic patients on a multiple daily injection regimen. A questionnaire study.
        Diabetologia. 1990; 33 (Abstract): A116
        • Brems DN
        • Alter LA
        • Beckage MJ
        • et al.
        Altering the association properties of insulin by amino acid replacement.
        Protein Eng. 1992; 5: 527-533
        • DiMarchi RD
        • Chance RE
        • Long HB
        • et al.
        Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I.
        Horm Res. 1994; 41 (Suppl 2): 93-96
        • Galloway JA
        • Chance RE
        Approaches to insulin analogs.
        in: Marshall SM Home PD Diabetes Ann. 8. Elsevier Science BV, Amsterdam1994: 277-297
        • Howey DC
        • Bowsher RR
        • Brunelle RL
        • Woodworth JR
        [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analog of human insulin.
        Diabetes. 1994; 43: 396-402
        • Brange J
        • Owens DR
        • Kang S
        • Vølund A
        Monomeric insulins and their experimental and clinical implications.
        Diabetes Care. 1990; 13: 923-954
        • Kang S
        • Owens DR
        • Vora JP
        • Brange J
        Comparison of insulin analog B9AspB27Glu and soluble human insulin in insulin-treated diabetes.
        Lancet. 1990; 335: 303-306
        • Kang S
        • Creagh FM
        • Peter JR
        • et al.
        Comparison of subcutaneous soluble human insulin and insulin analogs (AspB9, GluB27, AspB10, AspB28) on meal-related plasma glucose excursions in type 1 diabetic subjects.
        Diabetes Care. 1991; 14: 571-577
        • Nielsen FS
        • Jørgensen LN
        • Ipsen M
        • et al.
        Long-term comparison of human insulin analog B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen.
        Diabetologia. 1995; 38: 592-598
      1. WHO Expert Committee on Diabetes Mellitus.
        Second Report. WHO, Geneva1980 (World Health Organization, Techical Report Series: 646)
        • Schrifreen RS
        • Hickingbotham JM
        • Bowers GN
        Accuracy, precision and stability in measurement of haemoglobin A1c by high performance cation exchange chromatography.
        Clin Chem. 1980; 26: 3-7
        • Hoffmeister H
        • Junge B
        Uber die haltbarkeit von serumbestandteilen und die zuverlassigkeit ihrer bestimmung im autoanalyzer SMA 12-30-survey.
        Z Klin Chem Klin Biochem. 1970; 8: 613-617
        • Howey DC
        • Bowsher RR
        • Brunelle R
        • et al.
        [Lys(B28), Pro(B29)]-human insulin: Effect of injection time on postprandial glycemia.
        Clin Pharmacol Ther. 1995; 58: 459-469
        • The Diabetes Control and Complications Trial Research Group
        The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
        NEJM. 1993; 329: 977-986
        • Wang PH
        • Lau J
        • Chalmers TC
        Metaanalysis of effects of intensive blood glucose control on late complications of type I diabetes.
        Lancet. 1993; 341: 1306-1309
        • Reichard P
        • Nilsson B-Y
        • Rosenquist U
        The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus.
        NEJM. 1993; 329: 304-309
        • Stephenson J
        • Fuller JH
        • EURODIAB IDDM Complications Study Group
        Microvascular and acute complications in IDDM patients: The EURODIAB IDDM Complications Study.
        Diabetologia. 1994; 37: 278-285
        • Krolewski AS
        • Laffel LMB
        • Krolewski M
        • et al.
        Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus.
        NEJM. 1995; 332: 1251-1255
        • Uusitupa MIJ
        • Niskanen LK
        • Siitonen O
        • et al.
        Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in Type 2 (non-insulin-dependent) diabetic and non-diabetic subjects.
        Diabetologia. 1993; 36: 1175-1184
        • Kuusisto J
        • Mykkänen L
        • Pyörälä K
        • Laakso M
        NIDDM and its metabolic control predict coronary heart disease in elderly subjects.
        Diabetes. 1994; 43: 960-967
        • Kinmonth AL
        • Baum JD
        Timing of prebreakfast insulin injection and postprandial metabolic control in diabetic children.
        BMJ. 1980; 280: 604-606
        • Letiexhe MR
        • Rutters A
        • Schmitt H
        (Lys(B28), Pro(B29)) human insulin: Patients treated with lyspro vs human regular insulin: Quality of life assessment.
        Diabetologia. 1994; 37 (Abstract): A168
        • Torlone E
        • Pampanelli S
        • Lalli C
        • et al.
        Postprandial glycaemic control in IDDM after s.c. LYS, PRO insulin analogue or human regular insulin.
        Diabetes. 1995; 44 (Abstract): 71A
        • Ceriello A
        • Giacomello R
        • Stel G
        • et al.
        Hyperglycemia-induced thrombin formation in diabetes: The possible role of oxidative stress.
        Diabetes. 1996; 44: 924-928
        • Ceriello A
        • Taboga C
        • Tonutti L
        • et al.
        Post-meal coagulation activation in diabetes mellitus: The effect of acarbose.
        Diabetologia. 1996; 39: 469-473
        • Fineberg SE
        • Fineberg NS
        • Anderson JH
        • et al.
        Comparative immunogenicity of LysPro (B28, 29) human insulin analog between type I and type II patients.
        Diabetologia. 1994; 37 (Abstract): A168
        • Buelke-Sam J
        • Byrd RA
        • Hoyt JA
        • Zimmermann JL
        A reproductive and developmental toxicity study in CD rats of LY275585, [Lys(B28), Pro(B29)]-human insulin.
        J Am Coll Toxicol. 1994; 13: 247-260
        • Slieker LJ
        • Brooke GS
        • Chance RE
        • et al.
        Insulin and IGF-I analogs: Novel approaches to improved insulin pharmacokinetics.
        in: Leroith D Raizada MK Current Directions in Insulin-Like Growth Factor Research. Plenum Press, New York1994: 25-32